Effect of antiviral treatment on the shedding of HIV-1 in semen
|
|
- Isabella Shields
- 6 years ago
- Views:
Transcription
1 Effect of antiviral treatment on the shedding of HIV-1 in semen Pietro L. Vernazza*, Bruce L. Gilliam, Markus Flepp, John R. Dyer, Andreas C. Frank*, Susan A. Fiscus, Myron S. Cohen and Joseph J. Eron Objective: The potential role of antiretroviral treatment on the infectiousness of HIV- 1-infected men was examined by studying the effect of antiviral treatment on the shedding of HIV-1 in semen. Methods: Forty-four patients enrolled in various treatment protocols were asked to donate a semen sample before they began a new antiviral treatment and at a followup visit after 6 to 15 weeks of treatment. Since most patients were on blinded protocols, patients were stratified by response of blood viral load. The effect of each patient s treatment was classified as good (n = 24), fair (n = 8) and marginal (n = 13) by measurement of the HIV RNA reduction in blood plasma (> 1.0 log 10 ; log 10 and <0.5 log 10 HIV RNA copies/ml reduction, respectively). The effect of treatment on shedding of HIV-1 in semen was documented by the reduction of HIV RNA concentration in seminal plasma and by quantitative HIV-1 seminal cell culture. Results: Overall, antiviral treatment resulted in a significant fall in the viral load in semen (RNA and culture) that paralleled the reduction of viral load in blood. More pronounced reductions of HIV RNA in semen were observed as the effectiveness of treatment on blood HIV RNA levels increased (median drop from baseline 0, 0.3 log 10 and 0.8 log 10 RNA copies/ml in patients with marginal, fair and good treatment effect, respectively). Thirteen patients lost detectable HIV RNA in blood on treatment and all of these had undetectable levels of HIV-1 in semen by culture and RNA analysis at follow-up. In 19 of the 31 patients (62%) who still had HIV RNA in their blood during treatment, semen HIV levels were below detection in semen at follow-up. Conclusions: Treatment-induced changes of HIV RNA concentration in blood are generally associated with a corresponding change in seminal HIV RNA. If confirmed in larger studies, potent antiretroviral therapy might reduce the spread of HIV-1. AIDS 1997, 11: Keywords: Semen, sexual transmission, viral load, antiviral treatment, HIV RNA Introduction Recent advances in the development of antiviral treatment for HIV infection have resulted in therapeutic regimens that produce a marked suppression of viral replication and a significant extension of survival of infected individuals [1]. Suppression of HIV RNA in blood plasma to below the limit of detection has From the *Institute for Clinical Microbiology and Immunology and Department of Medicine, Kantonsspital, St Gallen, Switzerland, the Department of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA, the Department of Medicine, University Hospital Zurich, Zurich, Switzerland and the Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, North Carolina, USA. Sponsorship: Supported by the Swiss National Science Foundation and the Swiss Federal Office of Public Health ( and ), the Australian Society for Infectious Diseases, the Cooperative Agreement SU01AI25868 from NIAID, General Clinical Research Centers program NIH RR00046 and grant numbers UOAI31496 and NIDDK RO and by Pharmacia & Upjohn. The clinical research protocols in which some of the patients participated were supported by Pharmacia & Upjohn, Merck Research Laboratories and Hoffmann-La Roche. Requests for reprints to: Dr Pietro L. Vernazza, Institute for Clinical Microbiology, Kantonsspital, 9007 St Gallen, Switzerland. Date of receipt: 17 March 1997; revised: 29 April 1997; accepted: 6 May Rapid Science Publishers ISSN
2 1250 AIDS 1997, Vol 11 No 10 become a major goal of antiretroviral treatment strategies. Whether the benefit for the individual patient is matched by reduced spread of HIV-1 in the population is not known. Indeed, if transmission probability is not reduced by the treatment, the extension of the infectious period of infected individuals could lead to an increase of the AIDS epidemic [2,3]. Conversely, a treatment-induced reduction of the transmission probability might have a positive impact on public health. Preliminary evidence suggests that antiretroviral therapy might decrease transmission [4,5]. Because semen is an important vehicle for transmission of HIV-1 [3], we examined the effect of antiretroviral therapy on HIV RNA in blood and compared it with the shedding of HIV-1 in semen. Methods Patients and antiretroviral therapy The study was conducted at the three participating HIV clinics (St Gallen, n = 16; Chapel Hill, n = 14; Zürich, n = 14). Antiretroviral-naive patients (n = 19) starting a new antiretroviral treatment or drug-experienced patients who were changing treatment regimens (n = 25) were asked to participate in the study. Blood and semen samples were obtained prior to the start of the new antiviral treatment and at regular intervals thereafter. Only patients who gave semen and blood samples at baseline and between 6 and 15 weeks thereafter were included in this analysis. When patients provided multiple post-treatment samples, the sample that was given closest to 10 weeks after baseline was selected as the follow-up sample. Patients were stratified into good (n = 24), fair (n = 7) and marginal (n = 13) treatment effect by measurement of the HIV RNA reduction in blood plasma (> 1.0 log 10, log 10 and <0.5 log 10 copies/ml reduction, respectively). A more detailed presentation of the results from nine of the subjects was recently reported [5]. Quantification of HIV RNA in blood Blood samples were drawn within 24 h of the semen collection. Plasma was stored at 75 C until used for HIV RNA detection. HIV RNA concentration in blood was determined using reverse transcriptase (RT) polymerase chain reaction (PCR) assays [Roche, Basel, Switzerland (n = 35), Pharmacia Upjohn, Kalamazoo, Michigan, USA (n = 9)] [6]. The lower limit of detection of the RT-PCR assay was equivalent to 2.5 log 10 copies/ml in the Roche assay. Processing of semen samples and semen microculture assay Semen samples were obtained by masturbation into a sterile container. A virus transport medium (penicillin plus streptomycin) was added to each sample. Semen samples were processed in the laboratory within 2 4 h of ejaculation. Semen samples were centrifuged at 1000 g for 10 min and seminal plasma was removed and frozen in portions at 75 C. Seminal cells were washed twice in phosphate-buffered saline (PBS) and half of the seminal cells were used for quantitative HIV culture. Culture of seminal cells were performed as previously described [7,8] and results were expressed as infectious units per ejaculate. Quantitative detection of HIV RNA in seminal plasma HIV-1 RNA in cell-free seminal plasma was quantified using NASBA (Organon Technika, Durham, North Carolina, USA), as previously described [8,9]. The lower limit of detection of this assay was 1000 copies/ml. The dilution factor of the semen samples with known amounts of transport medium was taken into account for the final calculation of the HIV RNA concentration in seminal plasma. Statistical methods The respective changes of HIV RNA concentration in semen and blood were compared in the baseline and follow-up samples. Samples with HIV RNA concentrations below the limit of detection were assigned the value of the detection limit. Fisher s exact test or χ 2 test were used to compare distribution ratios. The Mann Whitney U test was used to compare median values of RNA and the Mc-Nemar test to compare fractions of patients with undetectable RNA pre- and post-treatment. Wilcoxon s signed rank test was used to compare pre- and post-treatment values from individual patients. Table 1. Baseline characteristics and antiviral treatment of study participants. Drug-naive Asymptomatic stage Mean CD4 count Median HIV RNA (blood) Treatment group (n)* [n (%)] (CDC A) n (%) (cells 10 6 /l) (log 10 copies/ml) A (2) 0 (0) 1 (50) B (5) 4 (80) 3 (60) C (16) 3 (19) 3 (19) D (21) 12 (57) 17 (81) All patients (44) 19 (43) 23 (56) *Treatment groups: A: monotherapy [zidovudine (1), indinavir (1)]; B: two reverse transcriptase inhibitors (RTI) (all zidovudine plus lamivudine); C: two RTI plus a protease inhibitor [ritonavir (14), indinavir (2)]; D: still blinded [zidovudine versus zidovudine plus zalcitabine versus zidovudine plus saquinavir versus zidovudine plus zalcitabine plus saquinavir (12); zidovudine versus zidovudine plus delavirdine (3); didanosine versus didanosine plus delavirdine (6)]. CDC, Centers for Disease Control and Prevention criteria.
3 Antiviral treatment and HIV-1 in semen Vernazza et al Results Forty-four patients were included in this study. Patients received either a triple-drug combination including a protease inhibitor (n = 14) or were assigned to one of four blinded protocols evaluating a combination of RT inhibitors with or without a protease inhibitor (n = 30). At the time of submission of the manuscript, the authors were still blinded for the treatment of 21 of the patients included in the study. Antiviral treatments used in this study are summarized in Table 1. At baseline, HIV RNA was detectable in the blood of all patients, with a median concentration of 4.9 log 10 copies/ml (range, ). HIV-1 RNA was detected in seminal plasma in 30 patients (68%) and HIV-1 was recovered in 16 (37%) by HIV-1 coculture of seminal cells (Table 2). All 14 patients with undetectable HIV RNA in seminal plasma also had negative HIV-1 seminal cell cultures at baseline. These findings are consistent with our previous results of a cross-sectional analysis of 101 patients [7]. Antiviral treatment resulted in a significant reduction of the median HIV-1 RNA level in blood and semen. The proportion of subjects with detectable virus in semen (either by HIV RNA assay or by culture) was significantly lower at follow-up (Table 2). When the treatment effect in blood was stratified, the reduction of HIV RNA concentration in semen was most apparent in patients with good treatment effect in blood. The median change of HIV RNA in semen was 0.8 log 10, 0.3 log 10 and 0 copies/ml in patients with good, fair and marginal treatment effect, respectively (Fig. 1). Thirty patients had detectable HIV RNA in semen at Table 2. Detection of HIV-1 in blood and semen pretreatment and on treatment. Baseline Follow-up P value HIV RNA in blood plasma (n = 44) Number detectable (%) 44 (100) 32 (73) < 0.001* Median (log 10 copies/ml) < Range (log 10 copies/ml) < HIV RNA in seminal plasma (n = 44) Number detectable (%) 30 (68) 12 (27) < 0.001* Median (log 10 copies/ml) 3.91 < 3.0 < Range (log 10 copies/ml) < < Seminal cell culture (n = 43) Number detectable (%) 16 (37) 5 (12) < 0.01* Range (IUPE) *Mc-Nemar test. Wilcoxon rank signed test. IUPE, Infectious units per ejaculate. baseline. Among those 30 subjects, the median HIV RNA level in semen at baseline was slightly higher in the 17 patients with good treatment effect compared with the 13 patients for whom treatment was less effective (4.82 versus 4.56 log 10 copies/ml). Despite this, individuals with good treatment effect were more likely to become HIV RNA-negative in the follow-up sample compared with subjects who received less effective therapy [Fig. 1; 14 out of 17 versus 6 out of 13; odds ratio (OR) 5.44, 95% confidence interval (CI): , P = 0.04]. Under treatment, 13 patients had a decrease in HIV RNA levels in blood to below the limit of detection. In this group of patients, HIV-1 was detectable in the baseline semen samples in eight and four patients by RNA and culture analysis, respectively. None of these Fig. 1. HIV RNA concentration in semen for patients were grouped by the effectiveness of treatment on blood HIV RNA levels, as described in the text. Each line represents one patient s log 10 -transformed HIV RNA levels (copies/ml) in semen at baseline (left) and during follow-up (right). Whisker s plots at left and right represent the range of HIV RNA values at baseline and follow-up, respectively. Comparisons of semen HIV RNA values at baseline and post-treatment were made using Wilcoxon s signed rank test.
4 1252 AIDS 1997, Vol 11 No patients had detectable HIV-1 in semen at followup either by HIV RNA measurement or by culture (Fig. 2). In contrast, among the remaining 31 subjects who did not achieve that degree of HIV RNA suppression in blood, clearance of HIV from semen was only observed in 12 out of 22 and 10 out of 12 patients by RNA or culture analysis, respectively (P = 0.02, in a comparison of RNA detection by Fisher s exact test). The treatment-induced reduction of HIV RNA in semen was compared with the corresponding reduction in blood in all patients where pre- and post-treatment measurements were above the detection limit of the method (n = 10). The change in HIV-1 RNA load associated with the antiviral treatment was similar in semen and blood (within 0.5 log 10 variation of the method) only one patient had a marked decrease (1.7 log 10 copies/ml) in HIV viral load in semen despite an insignificant (0.4 log 10 copies/ml) change in blood HIV- 1 viral load. Although, in general, the drop of HIV RNA in semen parallels the drop in blood, the limited sample size of this study precludes any conclusions on the correlation between the two compartments. Discussion Measurement of HIV RNA reduction in blood is a direct reflection of the degree of therapeutic effect and is an excellent prognostic marker for the effect of treatment on clinical outcome [10,11]. Since most of our patients were on blinded protocols, we analysed the effect of therapy on HIV shedding in semen using the degree of viral load suppression in blood as a marker. We chose the value of < 0.5 log 10 copies/ml for marginal treatment effect since this is the biological variability of the assay and chose 1.0 log 10 for the cutoff between fair and good treatment effect. Treatment resulted in a significant reduction in the proportion of men with detectable HIV-1 in both blood and semen as well as in a significant drop of median HIV RNA concentrations in both compartments. Patients receiving effective treatment (as defined by a drop of blood HIV RNA of more than 1 log 10 copy/ml) were significantly more likely to have seminal HIV RNA levels below detection after treatment compared with patients who had a less pronounced treatment effect in blood. This longitudinal study supports previous results from several cross-sectional studies that have documented an association of antiviral treatment with lower detection rates of HIV in semen [7,12 15] and extends our preliminary longitudinal results on nine patients [5]. The decrease in HIV-1 in semen to levels below the limit of detection in the majority of men treated with effective antiretroviral therapy raises the possibility that HIV-RNA in Semen Fig. 2. HIV RNA in semen (log 10 copies/ml) in 13 patients who had no detectable HIV RNA in blood during treatment. See Fig. 1 for details. effective antiviral treatment may result in a biologically relevant reduction of an individual s sexual infectiousness for HIV. The significance of this finding, however, needs further evaluation. First, the concentration of HIV-1 in semen does not necessarily correlate with infectiousness. Second, the role of cell-free versus cellassociated virus in the transmission of HIV-1 has yet to be determined. Third, infectious HIV-1 may be present in genital secretions at levels below the detection limit of the methods used in this study. However, even though a relative reduction in infectiousness of the donor may not reduce the chance of infection between discordant partners to zero, an overall reduction in infectiousness of HIV-positive persons in a population should result in a decrease in the spread (or reproductive rate) of the epidemic in that population[16]. Recent work from our group and others indicates that detectable amounts of HIV-1 in semen correlate with what is known about sexual transmission of HIV: the detection of HIV-1 both by seminal cell culture and HIV RNA measurement is enhanced in patients with low CD4 counts [7,12,17,18]. These observations correlate with epidemiological data showing increased transmission rates in partner studies from patients with lower CD4 counts and more advanced stages of disease [19 22]. Similarly, reduction of HIV RNA load in semen after treatment of sexually transmitted diseases [23] supports the findings of decreased transmission in populations who are treated for these diseases [24]. Longitudinal studies are under way to define further the role of HIV-1 in genital secretions for the transmission of HIV.
5 Antiviral treatment and HIV-1 in semen Vernazza et al In vitro studies indicate an important role of seminal lymphocytes for the transmission of HIV-1 to the cervical mucosa [25], though the precise contribution of cell-free and cell-associated virus in transmission of HIV-1 is unknown. The quantification of cell-free HIV RNA is more precise and sensitive than quantitative HIV culture from seminal cells. Even if future studies demonstrate that cell-free virus is not important for transmission, the correlation of HIV RNA detection with the cell culture method [7,18] supports the use of quantitative HIV RNA detection as a surrogate marker for the quantitative determination of cell-associated HIV-1 in semen. HIV-1 RNA levels in seminal plasma may also be a surrogate marker for infectiousness, just as HIV-1 RNA levels in blood have correlated with parenteral and vertical transmission [26 28]. The fact that RNA levels in blood correlate with RNA levels in seminal plasma, and blood RNA levels correlate with the likelihood of sexual transmission [29], also lends support to the hypothesis that HIV RNA levels in seminal plasma may correlate with infectiousness. The inoculum needed for efficient transmission of HIV-1 is not known. One drawback of our study is the high level of HIV RNA required for detection in semen. However, the similarity in the degree of HIV RNA reduction in semen and blood, in the 10 patients where this comparison was possible, suggests that a potent suppression of blood viral load might be paralleled by a similar effect in semen. One observation in our study that raises concern is the presence of detectable RNA in the semen of 10 men on therapy. The transmission of zidovudine-resistant virus has been documented [30]. The transmission of virus resistant to other agents, including protease inhibitors, could result in decreasing efficacy of antiretroviral treatment in the HIV-infected population over time. This study provides evidence that effective antiviral treatment can be expected to have a beneficial impact on the spread of the epidemic. Long-term studies of the effect of antiretroviral therapy on HIV-1 levels in semen need to be conducted to confirm these findings and to evaluate whether suppression of HIV in semen is persistent over time and whether HIV-1 resistance emerges in semen. Acknowledgements The authors thank W. Freimuth and L. Wathen of Pharmacia & Upjohn for their contributions. Special thanks to D. Feldman for editing the manuscript. References 1. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996, 276: Anderson RM, Gupta S, May RM: Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV- 1. Nature 1991, 350: Royce RA, Seny A, Cates W, Cohen MS: Sexual transmission of HIV: host factors that shape the epidemic and implications for prevention. N Engl J Med 1997, 336: Musicco M, Lazzarin A, Nicolosi A, et al.: Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Arch Intern Med 1994,154: Gilliam BL, Dyer J, Fiscus SA, et al.: Effects of reverse transcriptase inhibitor therapy on HIV-1 viral burden in semen. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15: Wathen LK, Nuorala KW, Patel RK, et al.: Validation of a quantitative DNA PCR assay for HIV-1 in human peripheral blood mononuclear cells. XI International Conference on AIDS, Vancouver, July 1996 [abstract 520]. 7. Vernazza PL, Gilliam BL, Dyer JR, et al.: Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 1997, 11: Dyer JR, Gilliam BL, Eron JJ, Grosso L, Cohen MS, Fiscus SA: Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA (TM) with Amplicor reverse transcription-pcr amplification and correlation with quantitative culture. J Virol Meth 1996, 60: van Gemen B, van Beuningen R, Nabbe A, et al.: A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J Virol Meth 1994, 49: O Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334: Katzenstein TL, Pedersen C, Nielsen C, Lundgren JD, Jakobsen PH, Gerstoft J: Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996, 10: Anderson DJ, O Brien TR, Politch JA, et al.: Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type-1 in semen. JAMA 1992, 267: Hamed KA, Winters MA, Holodniy M, Katzenstein DA, Merigan TC: Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. J Infect Dis 1993, 167: O Brien TR, Anderson DJ, Seage GR: Inverse association between zidovudine (AZT) therapy and the prevalence of HIV in semen. VII International Conference on AIDS, Florence, Italy, 1991 [abstract 3092]. 15. Seage G, Mayer K, Horsburgh C, et al.: Prospective evaluation of effect of zidovudine on detection of HIV-1 in semen. IX International Conference on AIDS, Berlin, Germany, 1993 [abstract 3291]. 16. Anderson RM: The transmission dynamics of sexually transmitted diseases: the behavioural component. In Infectious Diseases of Humans: Dynamics and Control. Edited by Anderson RM, May RM. Oxford: Oxford University Press, Vernazza PL, Eron JJ, Cohen MS, Vanderhorst CM, Troiani L, Fiscus SA: Detection and biologic characterization of infectious HIV- 1 in semen of seropositive men. AIDS 1994, 8: Speck C, Coombs R, Koutsky L, et al.: Rates and determinants of HIV-1 shedding in semen. XI International Conference on AIDS. Vancouver, Canada, 1996 [abstract 334]. 19. Goedert JJ, Eyster ME, Biggar RJ, Blattner WA: Heterosexual transmission of human immunodeficiency virus: association with severe depletion of T-helper lymphocytes in men with hemophilia. AIDS Res Hum Retrovirus 1987, 3: Seage GR, Horsburgh Jr CR, Hardy AM, et al.: Increased suppressor T cells in probable transmitters of human immunodeficiency virus infection. Am J Public Health 1989, 79: Seage GR, Mayer KH, Horsburgh Jr CR: Risk of human immunodeficiency virus infection from unprotected receptive anal intercourse increases with decline in immunologic status of infected partners. Am J Epidemiol 1993, 137:
6 1254 AIDS 1997, Vol 11 No Devincenzi I: Longitudinal study of human immunodeficiency virus transmission by heterosexual partners. N Engl J Med 1994, 331: Cohen MS, Hoffman IF, Royce RA, et al.: Treatment of urethritis reduces the concentration of HIV-1 in semen: implications for prevention of transmission of HIV-1. Lancet 1997 (in press). 24. Grosskurth H, Mosha F, Todd J, et al.: Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995, 346: Pearcepratt R, Phillips DM: Studies of adhesion of lymphocytic cells: implications for sexual transmission of human immunodeficiency virus. Biol Reprod 1993, 48: Busch MP, Operskalski EA, Mosley JW, et al.: Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. J Infect Dis 1996, 174: Fang GW, Burger H, Grimson R, et al.: Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995, 92: Sperling RS, Shapiro DE, Coombs RW, et al.: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996, 335: Lee TH, Sakahara N, Fiebig E, Busch MP, O Brien TR, Herman SA: Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12: Erice A, Mayers DL, Strike DG, et al.: Primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993, 328:
Quantification of HIV in semen: correlation with antiviral treatment and immune status
Quantification of HIV in semen: correlation with antiviral treatment and immune status Pietro L. Vernazza*, Bruce L. Gilliam, John Dyer, Susan A. Fiscus, Joseph J. Eron, Andreas C. Frank and Myron S. Cohen
More informationPotent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV
Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV Pietro L. Vernazza a,b, Luigi Troiani d, Markus J. Flepp e, Richard W. Cone e, Jody Schock c, Felix
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS
ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS Acquired immunodeficiency syndrome (AIDS ) is an infectious disease caused by a retrovirus, the human immunodeficiency virus(hiv). AIDS is
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Effect of Antiretroviral Therapy on Viral Load, CD4 Cell Count, and Progression to Acquired Immunodeficiency Syndrome in a Community Human Immunodeficiency Virus Infected Cohort
More informationThe Synergy between HIV and other STIs
Training Course in Sexual and Reproductive Health Research 2017 Module: Sexually transmitted infections, HIV/AIDS The Synergy between HIV and other STIs Alberto Matteelli Brescia University Sexual Transmission
More informationHIV/STDs and Excretion of HIV in Genital Secretions - Implications for sexual transmission. Pietro L. Vernazza, KSSG, St. Gallen, Switzerland
HIV/STDs and Excretion of HIV in Genital Secretions - Implications for sexual transmission Pietro L. Vernazza, KSSG, St. Gallen, Switzerland Where it all began... Vogt M, Lancet, 8. March 86 Schultz
More informationQUANTITATIVE HIV RNA (VIRAL LOAD)
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HIV RNA (VIRAL LOAD) Policy Number: PDS - 008 Effective Date: October
More informationQUANTITATIVE HIV RNA (VIRAL LOAD)
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HIV RNA (VIRAL LOAD) Policy Number: PDS - 008 Effective Date: January
More informationVirologic and CD4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment of Human Immunodeficiency Virus Infection
AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 17, Number 3, 2001, pp. 203 210 Mary Ann Liebert, Inc. Virologic and CD4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationSupplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.
Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,
More informationBJID 2001; 5 (August) 177. count and a mild decrease in viral load, patients tended to have an inverse correlation between the CD 4. counts [7].
BJID 2001; 5 (August) 177 Evaluation of Viral Resistance to Reverse Transcriptase Inhibitors (RTI) in HIV-1- Infected Patients Before and After 6 Months of Single or Double Antiretroviral Therapy Carlos
More informationDATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA.
Viral Load DNA >> Standard PCR standard 0 Copies Catalog Number: 1122 Lot Number: 150298 Release Category: A Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter
More informationImportance of Viral Suppression to Reduce HIV Transmission: Recent Evidence
Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine Viral suppression
More informationART FOR HIV PREVENTION: PANACEA OR PANDORA S BOX? KENNETH H. MAYER, M.D.
ART FOR HIV PREVENTION: PANACEA OR PANDORA S BOX? KENNETH H. MAYER, M.D. HIV TRANSMISSION SIGNIFICANT, LOW PROBABILITY EVENT (
More informationLong-Term Evaluation of T-Cell Subset Changes After Effective Combination Antiretroviral Therapy During Asymptomatic HIV-Infection
JAIDS Journal of Acquired Immune Deficiency Syndromes 27:266 271 2001 Lippincott Williams & Wilkins, Inc., Philadelphia Long-Term Evaluation of T-Cell Subset Changes After Effective Combination Antiretroviral
More informationStudy finds PEP not 100% effective in preventing HIV infection
From TreatmentUpdate 152 Study finds PEP not 100% effective in preventing HIV infection Some doctors and nurses who care for PHAs may sustain needle-stick injuries. This raises the possibility that they
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationQ and A - the PARTNER Study: new results from PARTNER 2
Q and A - the PARTNER Study: new results from PARTNER 2 1. Study results What is the PARTNER Study? The PARTNER study is an international two-phase study that looked at whether HIV transmission occurs
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationHydroxyurea with ddi or ddi/d4t: a novel approach to HIV therapy
National AIDS Treatment Advocacy Project Hydroxyurea with ddi or ddi/d4t: a novel approach to HIV therapy Results from several hydroxyurea (ddi+hydroxyurea) studies were reported at Vancouver (July `96)
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationOutline. HIV and Other Sexually Transmitted Infections. Gonorrhea Epidemiology. Epidemiology 11/2/2012
HIV and Other Sexually Transmitted Infections Tanya Kowalczyk Mullins, MD, MS Division of Adolescent Medicine Cincinnati Children s Hospital Medical Center Outline Epidemiology of select STIs and HIV STIs
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Rough K, Seage GR III, Williams PL, et al. Birth outcomes for
More informationMicropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ
www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons
More informationTime taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART
Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART Authors M A Ismail, E Okpo, S Baguley, A Butt, D Brawley, I Tonna 4 University of Aberdeen, MBChB Office, School
More informationPost-Sexual Exposure Prophylaxis (npep)
Projeto Praça Onze Universidade Federal do Rio de Janeiro Post-Sexual Exposure Prophylaxis (npep) Mauro Schechter Principal Investigator, Projeto Praça Onze Professor of Infectious Diseases Universidade
More informationORIGINAL INVESTIGATION. A Critical Assessment of the Prognostic Value of HIV-1 RNA Levels and CD4 + Cell Counts in HIV-Infected Patients
ORIGINAL INVESTIGATION A Critical Assessment of the Prognostic Value of HIV- RNA Levels and CD + Cell Counts in HIV-Infected Patients Sabine Yerly, MS; Thomas V. Perneger, MD, PhD; Bernard Hirschel, MD;
More informationSupplementary Material. In this supplement we derive the full form of the monetary and health costs of testing
Supporting document Supplementary Material In this supplement we derive the full form of the monetary and health costs of testing every years, and ; we derive the approximation shown in (1); and we justify
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationDecline of CD3-positive T-cell counts by 6 months of age is associated with rapid disease progression in HIV-1 infected infants
Decline of CD3-positive T-cell counts by 6 months of age is associated with rapid disease progression in HIV-1 infected infants Javier Chinen, Baylor College of Medicine Kirk Easley, Emory University Herman
More informationas patients may think? KSSG, St. Gallen, Switzerland
HIV in Semen - Is it as infectious as patients may think? Pietro L Vernazza Pietro L. Vernazza, KSSG, St. Gallen, Switzerland Heterosexual Transmission HIV-pos. HIV-neg. Clumeck N, et al, NEJM, 1989;321:1460
More informationART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationAdvances in HIV science and treatment. Report on the global AIDS epidemic,
HIV biomolecular advances and treatment updates David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia UNAIDS: global l HIV infections
More informationOverview of role of immunologic markers in HIV diagnosis
Overview of role of immunologic markers in HIV diagnosis Savita Pahwa, M.D. Departments of Microbiology & Immunology and Pediatrics University of Miami, Miller School of Medicine, Miami, Florida Background:
More informationVIRAL LOAD AND HETEROSEXUAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
VIRAL LOAD AND HETEROSEXUAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 THOMAS C. QUINN, M.D., MARIA J. WAWER, M.D., NELSON SEWANKAMBO, M.B., DAVID SERWADDA, M.B., CHUANJUN LI, M.D., FRED WABWIRE-MANGEN,
More informationSexual transmission of HIV: a heterogeneous event
Sexual transmission of HIV: a heterogeneous event Deutsch-Österreichischer AIDS Kongress Wien 1.-4. June 2005 Pietro L. Vernazza, Infectious Diseases, KSSG St. Gallen, Switzerland Heterosexual Transmission
More informationAlthough the public s awareness of infection with the
Results of a Physician Survey on Ordering Viral Load Testing Opportunity for Laboratory Consultation Louise K. Hofherr, PhD; Diane P. Francis, MPH, MT(ASCP); J. Rex Astles, PhD; William O. Schalla, MS
More informationCan HPV, cervical neoplasia or. HIV transmission?
Interactions between HPV and HIV: STIs and HIV shedding, regulation of HPV by HIV, and HPV VLP influence upon HIV Jennifer S. Smith Department of Epidemiology pd University of North Carolina Can HPV, cervical
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationEDMA HIV-AIDS TEAM Fact Sheet November 2007
EDMA HIV-AIDS TEAM Fact Sheet November 2007 1. HIV Facts AIDS epidemic update UNAIDS Epidemic Update, November 2007 (1) 760,000 people to be living with HIV in Western and Central Europe in 2007. 31,000
More informationIntroduction: Table/Figure Descriptions:
Introduction: We have completed the analysis of your HIV RNA Validation Study. The validation plan was designed to verify the installation of an unmodified FDA-approved HIV RNA assay into your laboratory.
More informationHIV-1 Viral Load Real Time (RG)
-1 Viral Load Real Time (RG) Real Time RT-PCR type 1 RNA quantification assay MSP Reg. pending Valdense 3616. 11700. Montevideo. Uruguay. phone (598) 2 336 83 01. Fax (598) 2 336 71 60. Info@atgen.com.uy
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Grgić I., Židovec Lepej S., Vince A., Begovac J. (2010) Increased frequency of viral loads above 100,000 HIV-1 RNA copies/ml measured by Roche Cobas TaqMan assay in comparison
More informationHIV/AIDS MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: HIV/AIDS MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN HIV/AIDS MEASURES GROUP: #159. HIV/AIDS: CD4+ Cell Count or CD4+ Percentage Performed #160. HIV/AIDS: Pneumocystis
More information3 rd International Workshop on Women and HIV January 14 th, 2013
3 rd International Workshop on Women and HIV January 14 th, 2013 Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on
More informationSexually Transmitted Infection Treatment and HIV Prevention
Sexually Transmitted Infection Treatment and HIV Prevention Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine STI Treatment and HIV Prevention.
More informationUnprotected sex in an STD clinic population: Agreement between self-reported condom use and PCR detection of y-chromosome in vaginal fluid
Unprotected sex in an STD clinic population: Agreement between self-reported condom use and PCR detection of y-chromosome in vaginal fluid Alia A. Al-Tayyib, MSPH 1, William C. Miller, MD, PhD, MPH 1,2,
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More informationCUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA. Date
CUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA 350 300 250 Number 200 150 100 50 0 1/01/1997 1/01/1998 1/01/1999 1/01/2000 31/12/2000 31/12/2001 31/12/2002 Date July 2004 Reported number of perinatally exposed
More informationTo interrupt or not to interrupt Are we SMART enough?
SMART To interrupt or not to interrupt Are we SMART enough? highly active antiretroviral therapy 5 1996 1997 10 25 43 45 35 metabolism 50 copies/ml lipodystrophy [fat redistribution syndrome] lactic acidosis
More informationHIV Prevention in US Women
HIV Prevention in US Women Sally L. Hodder M.D. Sally L. Hodder MD Professor of Medicine December 1, 2010 24, 2010 Overview Epidemiology of HIV in US women HIV testing Antiretroviral i treatment as HIV
More informationAntiviral Chemotherapy
Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationWomen and Viral Load. Together, we can change the course of the HIV epidemic one woman at a time.
Women and Viral Load Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Viral Load? Viral load is the amount of HIV (number of viruses
More informationTB/HIV/STD Epidemiology and Surveillance Branch. First Annual Report, Dated 12/31/2009
TB/HIV/STD Epidemiology and Surveillance Branch First Annual Report, Dated 12/31/29 This Enhanced Perinatal Surveillance Report is the first annual report generated by the Texas Department of State Health
More informationAIDS 2002, 16:381±385. Keywords: HAART, efavirenz, cohort study, matched case-control study, HIV, HIV protease inhibitors
Switching from protease inhibitors to efavirenz: differences in ef cacy and tolerance among risk groups: a case±control study from the Swiss HIV Cohort Bernard Hirschel a, Markus Flepp b, Heiner C. Bucher
More informationDiagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know
Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know Carolyn K. Burr, EdD, RN Co-Clinical Director Deputy Director François-Xavier Bagnoud Center December 17 th, 2013
More informationHerpes virus co-factors in HIV infection
Herpes virus co-factors in HIV infection Dr Jane Deayton Barts and the London Queen Mary School of Medicine Introduction Herpes viruses very common and often coexist with HIV Establish life-long latent
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationMolecular Diagnosis Future Directions
Molecular Diagnosis Future Directions Philip Cunningham NSW State Reference Laboratory for HIV/AIDS & Molecular Diagnostic Medicine Laboratory, SydPath St Vincent s Hospital Sydney Update on Molecular
More informationModernization of North Carolina s HIV control measures
Modernization of North Carolina s HIV control measures North Carolina Division of Public Health Victoria Mobley, MD MPH Evelyn Foust, MPH CPM Agenda Introduction Summary of scientific evidence used to
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationHIV/AIDS & Immune Evasion Strategies. The Year First Encounter: Dr. Michael Gottleib. Micro 320: Infectious Disease & Defense
Micro 320: Infectious Disease & Defense HIV/AIDS & Immune Evasion Strategies Wilmore Webley Dept. of Microbiology The Year 1981 Reported by MS Gottlieb, MD, HM Schanker, MD, PT Fan, MD, A Saxon, MD, JD
More informationHIV in Obstetrics and Gynecology
FAST FACTS HIV in Obstetrics and Gynecology Indispensable Guides to Clinical by J Richard Smith, Naomi Low-Beer and Bruce A Barron Practice HIV infection 7 Managing infected women 13 Preconceptual care
More informationPelagia Research Library. European Journal of Experimental Biology, 2015, 5(10):1-5
Available online at www.pelagiaresearchlibrary.com European Journal of Experimental Biology, 2015, 5(10):1-5 ISSN: 2248 9215 CODEN (USA): EJEBAU Molecular diagnosis of human immuno deficiency virus (HIV)
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More information(See the editorial commentary by Sasson et al. on pages 373 5)
MAJOR ARTICLE HIV/AIDS Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to!500 Cells/mL in HIV Type 1 Infected Individuals Receiving Potent Antiretroviral Therapy Gilbert R.
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationCONCISE COMMUNICATION
1688 CONCISE COMMUNICATION Vertical Transmission of Multidrug-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) and Continued Evolution of Drug Resistance in an HIV-1 Infected Infant Victoria A. Johnson,
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationReceived 6 January 1995/Returned for modification 23 February 1995/Accepted 13 March 1995
JOURNAL OF CLINICAL MICROBIOLOGY, June 1995, p. 1562 1566 Vol. 33, No. 6 0095-1137/95/$04.00 0 Copyright 1995, American Society for Microbiology Comparative Stabilities of Quantitative Human Immunodeficiency
More informationSEXUAL TRANSMISSION. SEXUAL TRANSMISSION under ART: Biological Considerations
SEXUAL TRANSMISSION under ART: Biological Considerations Dr Steve Taylor, MB ChB, FRCP, PhD Consultant Physician, HIV/GU Medicine, Lead Consultant HIV Services, Directorate of Sexual Medicine and HIV Birmingham
More information(Part 2): Epidemiology and Infectivity
PHI and Transmission Risk (Part 2): Epidemiology and Infectivity Christopher D. Pilcher, md Research Assistant Professor of Medicine, University of North Carolina, Chapel Hill Chapel Hill, North Carolina
More informationAntiretroviral therapy for patients with HIV disease
Br J Clin Pharmacol 1998; 45: 221 228 Antiretroviral therapy for patients with HIV disease M. Barry, 1 F. Mulcahy 2 & D. J. Back 1 1 Department of Pharmacology and Therapeutics, University of Liverpool,
More informationDownloaded from https://academic.oup.com/jid/article-abstract/183/1/23/ by guest on 11 February 2018
23 Early Human Immunodeficiency Virus (HIV) Infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: Risk Behaviors, Symptoms, and Early Plasma and Genital Tract Virus Load Connie
More informationNIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2012 June 11.
NIH Public Access Author Manuscript Published in final edited form as: J Acquir Immune Defic Syndr. 2001 February 1; 26(2): 170 175. Comparison of Techniques for HIV-1 RNA Detection and Quantitation in
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationSysmex Educational Enhancement and Development No
SEED Haematology No 1 2015 Introduction to the basics of CD4 and HIV Viral Load Testing The purpose of this newsletter is to provide an introduction to the basics of the specific laboratory tests that
More informationHIV - Life cycle. HIV Life Cyle
Human Immunodeficiency Virus Retrovirus - integrated into host genome ne single-strand RA 7,000 bases HIV1 > HIV2 > HIV0 Pathology Destruction of CD4+ T lymphocytes Loss of immune function pportunistic
More informationSensitivity of the Procleix HIV-1/HCV Assay for Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNA in a High-Risk Population
JOURNAL OF CLINICAL MICROBIOLOGY, July 2002, p. 2387 2391 Vol. 40, No. 7 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.7.2387 2391.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationHIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg
HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis
More informationDepression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention
The Alfred Hospital Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Final Report August 2005 Chief Investigator Associate Professor Anne Mijch Infectious Diseases
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationImmunologic and Virologic Disease Progression and Response to ART Across Geographic Regions: Outcomes from HPTN 052
Immunologic and Virologic Disease Progression and Response to ART Across Geographic Regions: Outcomes from HPTN 052 Mina C. Hosseinipour, MD, MPH Site Investigator UNC Project, Lilongwe, Malawi UNC School
More informationCascade of medical care to HIV-infected patients in Europe. Cristina Mussini
Cascade of medical care to HIV-infected patients in Europe Cristina Mussini UNAIDS: New HIV treatment target 90% of people tested 90% of people diagnosed with HIV on treatment 90% of people on treatment
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationSupporting Information
Supporting Information Horwitz et al. 73/pnas.35295 A Copies ml - C 3NC7 7 697 698 7 7 73 76-2 2 Days Gp2 residue G458D G459D T278A 7/36 N28 K D 28 459 A28T ID# 697 ID# 698 ID# 7 ID# 7 ID# 73 ID# 76 ID#
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationBasic facts about HIV and AIDS
Basic facts about HIV and AIDS Tiia Pertel Department of Public Health, University of Tartu Estonian Association of Sexual Health HIV the Human Immunodeficiency Virus) RNA-virus, belongs into the the family
More informationAn abuse of surrogate markers for AIDS. By David Rasnick Published online in British Medical Journal, March 8, 2003
An abuse of surrogate markers for AIDS. By David Rasnick Published online in British Medical Journal, March 8, 2003 It should come as a shock, no doubt, to learn that if three laboratory tests somehow
More informationHIV TRANSMISSION AND PREVENTION KENNETH H. MAYER, M.D. BROWN UNIVERSITY/MIRIAM HOSPITAL FENWAY COMMUNITY HEALTH 5/31/07
HIV TRANSMISSION AND PREVENTION KENNETH H. MAYER, M.D. BROWN UNIVERSITY/MIRIAM HOSPITAL FENWAY COMMUNITY HEALTH 5/31/07 Estimates of Per-Contact Risk of HIV Infection HIV TRANSMISSION SIGNIFICANT, LOW
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More informationRESEARCH. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study
Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study Jorge Del Romero, clinical researcher, 1 Jesús Castilla, consultant medical epidemiologist,
More informationComplicated viral infections
Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western
More information